The researcher at Tata Memorial Centre performed a genome analysis of the whole exome samples of 44 early-stage gallbladder cancer patient’s to identify the underlying mutation. G13d and G12V are two type of KRAS mutations, being the strongest activating mutation patients with the G12V mutation will not respond to the anti-EGFR therapy. More importantly, patients with G13D mutation respond nearly sixfold more than G12V.
Detecting KRAS mutation for gallbladder cancer patients will protect the G13D mutation patients from adverse effects of chemotherapy and will help to take the informed decision from patients about anti-EGFR therapy. Source: The Hindu
